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Purpose of study
Until recently, few prospective data existed to indicate
safety/efficacy of NVP with entry CD4 count restricted to
<250 (women) or <400 (men) cells/mm
3.T w op h a s eI V
trials, ARTEN and NEWART, compared virologic safety/
efficacy of NVP vs ATV/r on a background of TDF/FTC
in HIV+ patients within these CD4 ranges. NEWART
(US) was designed to be confirmatory of ARTEN and to
supplement ARTEN data [1].
Methods
In NEWART, treatment naïve patients were randomized
to open-label NVP 200mg BID (lead-in dose 200mg QD x
14 days) or ATV/r (300/100mg) plus TDF/FTC (300/
200mg). Women had CD4 counts (cells/mm
3) <250; men
<400. Primary endpoint was virologic response prior to
and at week 48 defined as confirmed HIV viral load (VL)
<50 copies/mL without subsequent rebound or therapy
change. A point estimate of -6.5% or higher for difference
in proportion of responders (NVP-ATV/r) was considered
consistent with a successful ARTEN study.
Summary of results
152 patients were treated: 89% male, 68% White, 31%
Black. At baseline, mean log10 VL was 4.9 and median
CD4 count (cells/mm
3) was 176 (NVP) and 193 (ATV/r).
Table 1 summarizes key outcome measures. Mean
plasma lipid (mg/dL) changes from baseline through 48
weeks (last observation carried forward) were as follows
(NVP and ATV/r arms, respectively): total cholesterol
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Table 1
Outcome Measure (48 wks) NVP 200 mg BID
(n=75)
ATV/r 300/100 QD
(n=77)
P
value
Difference (95% CI) from model
adjusting for screening VL and CD4+
Virologic Response (VR) 46 (61.3%) 50 (64.9%) 0.71 -4.1% (-18.3% to 10.1%)
Virologic Failure (VF), Protocol Defined 10 (13.3%) 12 (15.6%) 0.63 -2.6% (-13.1% to 7.9%)
Early withdrawals† 24 18
- due to investigator-defined VF 5 0
- due to adverse events 9* 9
- due to other reason 10 9
Mean Change in TC/HDLc [baseline to week 48
(LOCF)]
-0.38 -0.02 0.038 -0.33 (-0.64 to -0.02)
*NVP arm: 1 DAIDS grade 3 hepatobiliary AE (viral hepatitis); no grade 3/4 rash †2 deaths: 1-NVP (suicide); 1-ATV/r (lymphoma)
For NEWART and ARTEN (combined), VR for NVP 200mg BID was 65% (171/263) vs 65% for ATV/r (176/270) [P=0.75 (CI= -7.7% to 10.7%)].
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any medium, provided the original work is properly cited.(TC) 18.2 and 13.8 (P=0.73); HDL cholesterol (HDLc) 9.6
and 3.5 (P=0.016); LDL cholesterol (LDLc) 8.7 and 6.9
(P=0.93); and triglycerides -4.7 and 8.4 (P=0.36).
Conclusions
NVP + TDF/FTC was noninferior to ATV/r + TDF/
FTC. Although trial discontinuations were greater in the
NVP arm, VR was similar because of less documented
VF. HDLc increased and TC/HDLc decreased signifi-
cantly more for NVP than for ATV/r.
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